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Summary
Objectives: The French Society of Otorhinolaryngology (SFORL) set up a work group to draw
up guidelines for initial staging of head and neck squamous cell carcinoma. Locoregional and
remote extension assessment are dealt with in two separate reports. The present part 3 deals
with the assessment of frequent associated symptoms and pathologies, requiring early treat-Pharynx;
Larynx;
Initial staging;
ment and the collection of data on a certain number of clinical and paraclinical parameters for
therapeutic decision-making in the multidisciplinary team meeting.
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Anemia;
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Dental care
Materials and methods: A multidisciplinary critical analysis of the literature was conducted.
General assessment here covers screening, assessment and initial management of the following:
usual risk factors (smoking, alcohol, HPV), the most frequent medical comorbidities, nutritional
status, social and psychological status, dental status, pain and possible anemia. As oncologic
management frequently associates surgery, radiation therapy and chemotherapy, the under-
lying examinations should be early, as part of initial staging. The levels of evidence for the
examinations were estimated so as to grade guidelines, failing which expert consensuses were
established.
Results: The high rates of pain, malnutrition and anemia call for systematic screening and early
management, especially as rapidly effective treatments exist. Assessing comorbidity and social
and psychological status enables general health status to be assessed, along with possible con-
traindications to the usual treatments. Tracheal intubation problems may require intubation
under ﬂexible endoscopy or jet-ventilation by inter-cricothyroid catheterization from the diag-
nostic endoscopy stage. Assessment and adapted dental care should be conducted if radiation
therapy is likely or certain.
Conclusion: Early management of symptoms and comorbidity and anticipation of subsequent
treatment are intended to shorten initial staging time and to collate the data needed for
therapeutic decision-making. This assessment should be performed at the same time as the
locoregional and remote extension assessment, and is obviously to be adapted according to
tumoral extension stage and the possible treatment options.
© 2012 Elsevier Masson SAS. All rights reserved.
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re-therapeutic assessment of squamous cell carcinoma of
he oral, cavity larynx and pharynx (excluding the nasopha-
ynx) is controversial. Initial local and cervical lymph-node
ssessment, remote assessment and exploration for syn-
hronous second locations outside the upper aero-digestive
ract are dealt with in parts 1 and 2 of the present guide-
ines, published separately. The 3rd part of the present
uidelines of the French Society of ORL (SFORL) deals
ith general assessment: i.e., medico-social and psycholog-
cal parameters, cancer-related symptom management and
ssessment of contraindications to usual treatment modali-
ies.
ubjects and methods
hese guidelines were drawn up by a multidisciplinary
roup of experts in the ﬁeld: ENT specialists, and also
adiologists, maxillofacial surgeons, radiotherapists, medi-
al oncologists, pathologists, nuclear medicine specialists
nd anesthesiologists. The aim was to specify manage-
ent on the basis of a critical analysis of the literature
nd, where proof was lacking, to establish expert consen-
uses.
The ﬁeld covered by general assessment was deﬁned as
omprising:
medico-social and psychological assessment;
screening for and management of the three most frequent
symptoms (pain, malnutrition and anemia);
and pre-planning for possible surgery, radiation therapy
and chemotherapy and the associated issues of tracheal
intubation, dental care and reconstructive surgery.The levels of evidence of the selected articles were
oted so as to grade the guidelines in line with the
rench health authority (HAS) guide to literature analysis
nd guideline grading, itself based on the Sackett scoring
ystem.
ection 1: medico-social and psychological
ssessment
Guideline 1: Screening for and assessment and
management of head and neck cancer risk factors:
• genetic testing is not recommended as part of head
and neck cancer assessment (Grade A);
• in case of smoking and/or alcohol intoxication, the
following should be noted in the medical records:
◦ smoking level (pack-years) and duration,
◦ units of alcohol consumed/day;
• for both toxins, it should be noted whether intoxica-
tion is on-going or for how long abstention has been
genuine (Grade A);
• regular cannabis consumption should be investigated
(Grade A);
• exposure to asbestos, diesel fumes, nickel or pes-
ticides should be investigated. Construction and
agriculture are occupational sectors especially con-
cerned: head and neck cancer patients, with or
without nicotine/alcohol intoxication, working in
these sectors should be referred to an occupational
physician to specify exposure and for the patient’s
case to be registered (professional consensus);
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• clinical signs of gastro-esophageal reﬂux (GER)
should be systematically investigated, as it may be
a co-factor for certain head and neck cancer loca-
tions, notably larynx and hypopharynx (professional
consensus);
• systematic exploration for HPV is not recommended,
in absence of therapeutic impact (professional
consensus).
In the particular case of oropharyngeal carci-
noma and/or in absence of alcohol/nicotine-related
risk factors, immunohistochemical analysis by anti-P16
antibody is optional for epidemiological purposes (pro-
fessional consensus).
The main risk factors are alcohol and smoking; double
intoxication exerts a synergic effect on onset of head and
neck squamous cell carcinoma [1]. It is essential to take full
account of these risk factors; cessation immediately follow-
ing diagnosis improves treatment tolerance and thus limits
the risk of evolution. Silverman et al. reported 18% onset of
second cancer in smokers who ceased smoking, compared to
30% in those who did not [2].
HPV infection is mainly implicated in the oncogenesis
of oropharyngeal and oral cavity tumors, independently of
nicotine/alcohol intoxication [3,4]. St Guily et al., in a
prevalence study of 523 patients, found HPV in 46.5% of
oropharyngeal and 10.5% of oral cavity squamous cell carci-
nomas [5].
A literature review implicated HPV in 25.9% of 5046 head
and neck squamous cell carcinomas, taking all locations
together; for oropharynx, oral cavity and larynx, rates were
respectively 35.6%, 23.5% and 24% [6]. These ﬁndings were
conﬁrmed by Hobbs et al.’s meta-analysis of HPV-16, which
found a weaker association with laryngeal (odds ratio (OR):
2.0) than tonsillar cancer (OR: 15.1) [7]. Prognosis is fairer
in HPV-positive than HPV-negative oropharyngeal tumor [8].
Also to be borne in mind are:
• the impact of immunosuppression, notably in graft recip-
ients;
• the impact of cannabis consumption [9];
• the possible co-factor impact of GER, for which literature
reports are contradictory [10].
Guideline 2: exploration for comorbidities:
• comorbidity should be explored for and assessed so
as to be taken into account in therapeutic decision-
making (Grade B);
• treating comorbidity improves survival and quality of
life (Grade B);
• awareness of comorbidities is essential for the multi-
disciplinary team meeting (professional consensus).
s
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Comorbidity mainly comprises cardiovascular and respi-
atory pathology, diabetes, obesity, gastro-intestinal pathol-
gy, neurological pathology and synchronous cancer outside
he upper aero-digestive tract.
Comorbidity is a major prognostic factor in head and
eck squamous cell carcinoma, increasing immediate post-
reatment mortality [11]. Complications are signiﬁcantly
ore numerous and severe in case of comorbidity [12]. Diag-
osis is frequently delayed, with negative impact on quality
f life and recurrence-free survival [11—13].
Optimizing the general health status of head and neck
ancer patients could reduce morbidity, complications and
hus management costs.
Age is not a comorbidity as such, but comorbidities are
ore frequent in the elderly. This is, of course, taken into
ccount in therapeutic decision-making for elderly patients,
n whom assessment and pre-treatment management of
omorbidity plays a major role [14].
Guideline 3: social and psychological assessment
Guideline (Grade B)
Certain items should be systematically detailed in
the patient’s ﬁle:
• living conditions and quality of immediate social
environment: couple (status of partner), alone but
not isolated (family, friends, children), seriously iso-
lated, dependent, etc.;
• occupational situation and leisure;
• psychological status at diagnosis: screen for and
note known severe depression, anxiety level (French
health authority [HAS] scale), psychiatric history;
• need for consultation with psychologist or social
worker.
Babin et al. found that the numerous studies of post-
reatment quality of life failed to explore all domains
notably, daily life conditions, social relations and leisure),
r the inﬂuence of anticipated quality of life on initial
reatment choice [15]. Head and neck cancers have the par-
icularity of altering physical appearance and phonation and
wallowing functions, with serious impact on social life, thus
reatly inﬂuencing therapeutic decision-making and patient
cceptance; the patient’s psychological context and living
onditions also have great inﬂuence.
Two recent studies on ENT cancer patients reported a 6%
o 15% rate of depression and 12% to 30% of anxiety [16];
uicide rates are among the highest, just after those for
ronchopulmonary or gastric cancer [17].
The patient’s living conditions need to be known so as
o organize the treatment period and discharge home. As
reatment can sometimes be hard to tolerate or may induce
equelae, many patients have to take time off work and/or
ocial life, leading to serious social isolation [18].
The quality of the patient’s immediate social environ-
ent is an important factor in rehabilitation quality and
cceptance of disability [19].
1 E. de Monès et al.
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Guideline 5: screening for and management of pain:
• symptoms of pain should be investigated and man-
aged;
• the patients should be referred to algology if clas-
sic treatments fail to control the pain (professional
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ection 2: screening for and management of
hree frequent symptoms
Guideline 4: screening for and management of mal-
nutrition:
• weight, height and body-mass index (BMI:
weight/height2) and percentage recent weight-
loss should be measured in the initial head and neck
cancer consultation (Grade C);
• malnourished patients should be referred for dietary
consultation as soon as possible after cancer diagno-
sis (professional consensus);
• satisfactory oral feeding may require medical pre-
scription of analgesics and/or local anesthetics
(professional consensus).
Head and neck cancer patients run a serious risk of
ndernourishment due to an often disadvantaged socio-
ccupational situation, frequent alcohol/nicotine intoxica-
ion and, above all, pain and dysphagia.
Malnutrition prevention and screening should be sys-
ematic as from initiation of management. BMI inferior to
8.5 kg/m2 correlates signiﬁcantly with reduced overall sur-
ival [20].
As a complement to history taking with estima-
ion of weight-loss and BMI, albuminemia assay allows
he Buzby nutrition risk index (NRI = 1.519× [albumin in
/L] + 0.417× [present weight / usual weight]× 100) to be
alculated; NRI inferior to 83.5 indicates severe malnutri-
ion.
The recommended daily calorie intake is around 1600 to
400 kcal, and nitrate intake around 0.2 to 0.35 g/kg/day, or
.25 to 1.85 g of protein/kg/day (professional consensus).
f the oral route does not allow sufﬁcient intake, enteral
eeding should be initiated on medical decision, either by
asogastric tube or by gastrostomy.
Certain authors, such as Silander et al., have reported
hat early gastrostomy improved nutritional status during
reatment [21]. Mahdoun et al., however, reported that 11
ut of 23 patients ﬁtted with a prophylactic gastrostomy
ube used it either never or for less than 2weeks [22].
n patients at high-risk of dysphagia and choking before,
uring and after treatment, prophylactic gastrostomy should
e considered (professional consensus).
Peri-operative immunonutrition can signiﬁcantly reduce
he rate of complications [23], but is not presently covered
y the French health insurance system in head and neck
ncology.
Pain is frequent in head and neck cancer; it should be
anaged as of the ﬁrst consultation, as it may induce mal-
utrition by impaired feeding. History taking and clinical
xamination should detail the characteristics of pain so as
o adapt treatment.Pain due to excessive nociception requires:
step 1 (paracetamol, non-steroid anti-inﬂammatories);
s
s
cconsensus)
step 2 (minor morphine derivatives such as codeine, a
dihydrocodeine or tramadol);
or step 3 analgesia (morphine derivative or similar) [24].
For neuropathic pain, anti-epileptics (gabapentin or pre-
abalin) or antidepressants (imipramine, amitriptyline) or
ocal topical analgesics may be introduced [25]. For mixed
ain, double-action molecules (tramadol, oxycodone) are
ecommended in ﬁrst line. Treatment frequently associates
elayed and rapid action forms to achieve balance and deal
ith paroxysmal breakthrough pain. Side-effects such as
ausea or constipation require special prevention in these
ften undernourished patients: rigorous respect of dietary
ealth rules (hydration, ﬁber-rich diet, regular physical
xercise) and laxatives.
The form of treatment should be adapted to the patient’s
ymptoms: e.g., dysphagia or choking, where percutaneous,
ransmucosal or enteral (nasogastric or gastrostomy tube)
outes may be useful. Co-analgesic treatment may be associ-
ted: corticosteroids, local topical analgesics (anesthetics,
ealing agents, NSAIs) or antispasmodics.
Guideline 6: screening for and management of ane-
mia:
• anemia is an independent risk factor for poor prog-
nosis;
• it should be screened for, and managed by adapted
diet, possibly with i.v. or oral iron supplementation
(Grade B);
• indications for allogenic transfusion should be
limited (Grade A);
• transfusion strategy should therefore take account of
hemoglobinemia, comorbidity and surgical context
(Grade C).
Head and neck cancer patients are often found to be
nemic at initial staging [26]. There may be several rea-
ons for this: malnutrition due to underfeeding induced
y underlying symptoms (odynophagia, dysphagia, chok-
ng), chronic blood loss due to hemorrhagic tumor, chronic
nﬂammatory syndrome of tumoral or infectious origin (e.g.,
ronchopulmonary infection due to iterative false passage),
r unbalanced diet entailing deﬁciencies (frequent exces-
ive alcohol consumption).Anemia should be detected and corrected during initial
taging, being an independent factor of poor prognosis. It
an exacerbate postoperative complications [27—29], and
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reduce efﬁcacy and tolerance in concomitant radiation or
chemotherapy [30].
Adapted diet with iron supplementation is usually effec-
tive. Several recent publications showed parenteral iron
supplementation to be better and more effective than oral
route [31,32]. Peri-operative parenteral iron supplemen-
tation limits anemia secondary to surgical hemorrhage [33];
oral administration is slower acting and may be poorly toler-
ated. Hematopoietic growth factors, such as erythropoietin,
are controversial: while effective against anemia, they have
failed to show impact on local control and survival [34,35].
The policy of reducing recourse to homologous transfu-
sion applies in head and neck oncology as in other ﬁelds,
given that the associated morbidity is non-zero. When per-
formed, it should take account of total forecast surgical
blood-loss, any cardiopathy, pre-operative hemoglobine-
mia or hematocrit, and individual total blood volume.
Homologous red blood-cell transfusion guidelines, recom-
mended here, were drawn up by the French national
health products safety agency (Agence Franc¸aise de Sécurité
Sanitaire des Produits de Santé: AFSSAPS) in 2003 [36]. Rec-
ommended thresholds depend on whether anemia is acute
(7 to 10 g/L) or chronic (6 to 10 g/L), and take account of
cardiovascular history and tolerance.
Section 3: treatment pre-planning
Guideline 7: dental assessment and care:
• clinical and panoramic X-ray dental assessment
should be systematic in head and neck carcinoma
ahead of treatment (Grade C);
• any extractions should be performed as soon as
possible before radiation therapy or brachytherapy,
with treatment initiated only after gum mucosa
has healed and at a minimum 2weeks (professional
consensus);
• ﬂuoride protection should be implemented after
radiation therapy involving the head and neck (Grade
C). The ﬂuoride application splints are produced in
advance;
• a prosthetic rehabilitation consultation should be
set up before any maxillary surgery (professional
consensus);
• clinical and radiological dental assessment should
be performed ahead of chemotherapy, especially
when there is risk of medullary aplasia (professional
consensus).
The objectives of dental assessment as part of initial head
and neck cancer staging are:
• to treat acute or latent infection sites liable to induce
locoregional (e.g., delayed bone healing) or general (e.g.,
septicemia during aplasia-inducing chemotherapy) infec-
tion during treatment;
• to anticipate possible prosthetic rehabilitation ahead of
any surgery sacriﬁcing maxillary bone;and pharynx 169
and to reduce the risk of subsequent maxillary or
mandibular osteoradionecrosis (ORN) in the irradiated
area by completing appropriate dental care (conservative
or other) ahead of radiation therapy [37].
Dental assessment should systematically comprise metic-
lous clinical examination and panoramic dental X-ray
professional consensus). Exploration for latent dental infec-
ion sites may require retro-alveolar views, cone-beam or
entaScan.
Dental care may be conservative or not. In case of
xtraction, a minimum 2-weeks’ interval should be observed
efore initiating radiation therapy, to allow the bone and
ucosa to heal; this should limit, without entirely eliminat-
ng, the risk of ORN [38,39].
Cervicofacial radiation therapy entails a risk of deﬁni-
ive xerostomia. Fluoride protection of the remaining teeth
s indicated at end of treatment [40,41]. This consists of
aily 5—10minutes application of a ﬂuoridated gel (Fluo-
aryl Bi Fluoré 2000 gel©, Sensigel©, Emoform gel©) using a
edicated splint. Treatment should be on a lifetime basis, so
ong as any teeth remain. The ﬂuoride application splints are
sually ﬁtted ahead of radiation therapy, so that ﬂuoridation
an be initiated as quickly as possible at end of treatment.
Guideline 8: tracheal intubation and ventilation:
• the SFAR guidelines for difﬁcult intubation apply to
head and neck cancer patients (Grade A);
• inter-cricothyroid membrane palpation and investi-
gation of previous cervical radiation therapy should
look for signs predicting difﬁculties of intubation or
mask ventilation (Grade B);
• intubation under ﬂexible endoscopy is the technique
of choice in case of ENT neoplasia (Grade B);
• supraglottic devices should be avoided (Grade B);
• transtracheal ventilation needs to be well-controlled
(Grade B); a jet-ventilation device with tracheal
pressure control is to be preferred (Grade C).
Head and neck cancer patients are considered at risk
or tracheal intubation failure [42]. Various problems may
rise: obstructive or hemorrhagic tumor, oral cavity open-
ng restricted by tumoral invasion of the mastication space,
nd sequelae from previous treatment of a metachronous
econd tumor (history of cervical surgery and/or radiation
herapy).
There are two ways of getting round such problems in
nitial diagnostic endoscopy [43]:
nasotracheal intubation under nasoﬁbroscopy is the
method of choice when intubation difﬁculties are
expected. It may be performed under local (nasal and
pharyngolaryngeal) anesthesia or light sedation [44];
high-frequency jet ventilation via a transtracheal inter-
cricothyroid catheter ﬁtted under local anesthesia is an
interesting and reliable option [45,46]. Although con-
sidered invasive, associated morbidity is minimal when
the team is experienced. A device equipped with safety
features avoids pressure trauma. The technique has the
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advantage of avoiding the airway obstacle during insufﬂa-
tions, but requires the absence of any major obstacle to
expiration.
Coordination with the surgery team is essential for
creening patients for intubation issues. Emergency tra-
heotomy during diagnostic endoscopy without controlled
entilation should be a rare event, but cannot always be
voided.
Guideline 9: chemotherapy work-up:
• indications for chemotherapy should be raised in
the multidisciplinary team meeting (professional
consensus);
• general health status and comorbidity (cardiac,
renal, hepatic, neurologic) should be taken into
account ahead of chemotherapy (Grade D);
• onco-geriatric consultation ahead of chemotherapy
is recommended in elderly patients (Grade D);
• a complete blood count and liver assessment should
be performed ahead of chemotherapy (Grade A);
• renal assessment with creatinine clearance is rec-
ommended for chemotherapy including cisplatin or
carboplatin (Grade A);
• ECG should be performed ahead of 5-ﬂuorouracile
(5FU) chemotherapy (Grade A).
The main anticancer molecules used in initial curative
reatment for head and neck squamous cell carcinoma
re: platins (cisplatin or carboplatin), 5FU, docetaxel
Taxotère®), and cetuximab (Erbitux®). They may be used
lone in adjuvant chemotherapy or associated to radiation
herapy (radiochemotherapy or potentialized radiotherapy).
Generally speaking, the use of an anticancer molecule
s decided in the multidisciplinary team meeting, taking
ccount of the patient’s health status and comorbidities.
ny intensiﬁcation should weight beneﬁt against risk. In
atients over 70 years of age, beneﬁt is less obvious and
n onco-geriatric consultation may help in decision-making
47].
Preliminary examinations depend on the known toxicity
f the various molecules:
platinum (cisplatin and carboplatin) toxicity is mainly
hematologic, renal and neurologic. Work-up should com-
prise:
◦ renal function, with creatinemia and renal clearance
(Cockcroft-Gault or MDRD (modiﬁcation of diet in renal
disease) formula);
◦ and screening for peripheral neuropathy (alcohol-
related, diabetic) and hearing loss, with clinical
neuro-monitoring throughout treatment. The hyper-
hydration required with cisplatin 100mg/m2 may be
a problem in case of cardiac impairment; in case of
known or suspected cardiac insufﬁciency, specialist
advice is recommended;
ﬂuorouracil toxicity is hematologic, mucosal, cutaneous
(hand-foot syndrome) and cardiac. Cardiac toxicity
shows as arrhythmia and angina syndrome or myocardial oE. de Monès et al.
infarction. ECG is essential. Specialist cardiological advice
is recommended in case of risk factors for coronaropathy
or of abnormal ECG. DPD (dihydropyrimidine dehy-
drogenase) deﬁciency is a risk factor for overdosage;
individualized pharmacokinetic dosing can enhance toler-
ance without reducing efﬁcacy [48]; systematic screening
for DPD deﬁciency is currently recommended only in clin-
ical trials;
docetaxel (Taxotère®) toxicity is hematologic, and may
induce hypersensitivity reaction, reversible alopecia,
unguinal disorder or peripheral edema; it is greatly exac-
erbated by associated disorder seen on liver assessment:
hepatic biology analysis is essential;
cetuximab (Erbitux®) may induce allergic reaction of vary-
ing severity, up to anaphylactic shock, but does not show
renal, hematologic, neurologic or cardiac toxicity. It fre-
quently leads to acne-like skin rash, and sometimes to
diarrhea. No speciﬁc work-up is recommended.
Guideline 10: work-up for microanastomosed free-
ﬂap cervicofacial reconstruction:
• possible ﬂap harvesting sites should be checked
before beginning reconstruction (professional
consensus);
• before creating the free ﬂap, cervical vasculariza-
tion should only be investigated in case of doubt:
i.e., when clinical and/or radiological evidence casts
doubt on receiver network quality (e.g., known
atheromatous disease) (professional consensus);
• Allen’s test should be performed before harvesting
an antebrachial ﬂap (Grade D); echo-Doppler should
be performed in case of the slightest doubt (Grade
D);
• lower-limb angio-CT or angio-MRI should be per-
formed before creating a ﬁbular ﬂap (Grade C);
• angio-CT or angio-MRI should be performed before
creating an anterolateral thigh or deep inferior epi-
gastric perforator (DIEP) ﬂap (Grade C);
Head and neck cancer treatment has beneﬁted from
ecent progress in reconstructive surgery, improving esthetic
nd functional results. Microanastomosed free ﬂaps have
roved preferable to pediculated ﬂaps in terms of plastic-
ty, with improved adaptation to the defect, and of the
ange of available tissues. They are not, however, always
easible. At initial staging, if surgery is considered, the pos-
ibilities of reconstructive surgery should be assessed. After
istory-taking and appropriate clinical examination, certain
adiological examinations may be required.
There are two rules for microanastomosed free ﬂaps: to
heck:
receiver vessel quality (cervical arteries and veins);
and the feasibility of donor site harvesting without com-
promising residual tissue vascularization.
Carotid and jugular permeability can be assessed
n echo-Doppler or contrast-enhanced cervicofacial CT
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(angio-scan) [49,50]. However, this is recommended only in
case of doubt: i.e., when clinical and/or radiological evi-
dence casts doubt on receiver network quality (e.g., known
atheromatous disease); these examinations are not manda-
tory. When doubt persists, the free ﬂap should be performed
only once the surgeon has checked receiver vessel quality.
Donor site assessment depends on the type of ﬂap vas-
cularization. If a main terminal vascular axis is to be
sacriﬁced, the intended collateral network should be
checked. For antebrachial fasciocutaneous ﬂap sacriﬁcing
the radial artery, Allen’s test theoretically conﬁrms the qual-
ity of the ulnar artery and permeability of the superﬁcial
and deep palmar arches [51]. As its sensitivity is not opti-
mal, Allen’s test should be performed peroperatively, or
an echo-Doppler performed pre-operatively [52]. For ﬁbu-
lar ﬂap sacriﬁcing the posterior tibial artery, pre-operative
radiological vascular exploration is essential [53]; lower-
limb angio-CT or angio-MRI are preferable to echo-Doppler
in terms of effectiveness and reproductibility in diagnosing
anatomic variants in the mode of division of the popliteal
artery [54].
Fasciocutaneous ﬂaps with perforating artery pedicle
(scapular and parascapular, anterolateral thigh, DIEP, exter-
nal brachial ﬂaps) show less donor-site morbidity, but are
more difﬁcult to harvest. Pre-operative location of the per-
forating arteries on echo-Doppler or cross-sectional imaging
(angio-CT or angio-MRI) is recommended, and has been
shown to improve the reliability of and time needed for ﬂap
harvesting [55].
Conclusions
Early management of symptoms and comorbidity and treat-
ment pre-planning seek to reduce initial staging time, to
collate data for therapeutic decision-making, and to prepare
the patient for treatment. Assessment should be performed
at the same time as the locoregional and remote extension
assessment. It should be adapted to tumor stage and to the
possible treatment options.
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